Early assessment of responsive neurostimulation for drug-resistant epilepsy in China: A multicenter, self-controlled study

被引：0

作者：

Yang Yanfeng ^{[1
]}

Wei Penghu ^{[1
]}

Shi Jianwei ^{[1
]}

Mao Ying ^{[2
]}

Zhang Jianmin ^{[3
]}

Lei Ding ^{[4
]}

Yang Zhiquan ^{[5
]}

Song Shiwei ^{[6
]}

Qian Ruobing ^{[7
]}

Li Wenling ^{[8
]}

Shan Yongzhi ^{[1
]}

Zhao Guoguang ^{[1
]}

机构：

[1] Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China

[2] Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China

[3] Department of Neurosurgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

[4] Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan, China

[5] Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China

[6] Department of Neurosurgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China

[7] Department of Neurosurgery, The First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Hospital, Hefei, Anhui, China

[8] Department of Neurosurgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

来源：

中华医学杂志英文版 | 2025年 / 138卷 / 04期

关键词：

Neuromodulation; EpilcureTM; Focal epilepsy; Seizure control; Responsive neurostimulation;

D O I：

暂无

中图分类号：

R742.1 [癫痫];

学科分类号：

1002 ;

摘要：

Background: To evaluate the efficacy and safety of the first cohort of people in China treated with a responsive neurostimulation system (EpilcureTM, GenLight MedTech, Hangzhou, China) for focal drug-resistant epilepsy in this study.Methods: This multicenter, before-and-after self-controlled study was conducted across 8 centers from March 2022 to June 2023, involving patients with drug-resistant epilepsy who were undergoing responsive neurostimulation (RNS). The study was based on an ongoing multi-center, single-blind, randomized controlled study. Efficacy was assessed through metrics including median seizure count, seizure frequency reduction (SFR), and response rate. Multivariable linear regression analysis was conducted to explore the relationships of basic clinical factors and intracranial electrophysiological characteristics with SFR. The postoperative quality of life, cognitive function, depression, and anxiety were evaluated as well.Results: The follow-up period for the 19 participants was 10.7 ± 3.4 months. Seizure counts decreased significantly 6 months after device activation, with median SFR of 48% at the 6th month (M6) and 58% at M12 (P <0.05). The average response rate after 13 months of treatment was 42%, with 21% (n = 4) of the participants achieving seizure freedom. Patients who have previously undergone resective surgery appear to achieve better therapeutic outcomes at M11, M12 and M13 (β <0,P <0.05). No statistically significant differences were observed in patients’ scores of quality of life, cognition, depression and anxiety following stimulation when compared to baseline measurements. No serious adverse events related to the devices were observed.Conclusions: The preliminary findings suggest that EpilcureTM exhibits promising therapeutic potential in reducing the frequency of epileptic seizures. However, to further validate its efficacy, larger-scale randomized controlled trials are required.Registration: Chinese Clinical Trial Registry (No. ChiCTR2200055247)

引用